Liposomal Bupivacaine for Healthy Volunteers
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you stop taking opioid medications and NSAIDs (non-steroidal anti-inflammatory drugs) at least 3 days before the study drug is given. If you are on neuromodulating agents for pain control, you cannot participate, but if you take them for other reasons, you must be on a stable dose for at least 1 month before the study.
What data supports the effectiveness of the drug Liposomal Bupivacaine 13.3?
Is liposomal bupivacaine safe for humans?
How is liposomal bupivacaine different from other drugs?
What is the purpose of this trial?
This trial tests a new slow-release pain-relief drug called Liposomal Bupivacaine 13.3 in healthy adults to ensure it is safe and well-tolerated. Liposomal bupivacaine is designed to provide extended postsurgical pain relief and reduce opioid consumption.
Research Team
Sergey Zaets
Principal Investigator
Pacira Pharmaceuticals, Inc
Eligibility Criteria
Healthy adults aged 18-50, with no history of severe headaches, back conditions, or chronic pain. Participants must not have allergies to study medications like bupivacaine and should not be on certain medications like corticosteroids before the trial. Women must not be pregnant or nursing.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single intrathecal injection of Liposomal Bupivacaine 13.3, bupivacaine, or placebo, followed by a 5-day stay in the Early Phase Research Unit
Follow-up
Participants are monitored for safety and effectiveness after treatment, including a follow-up visit on Day 9 and a phone call on Day 30
Treatment Details
Interventions
- Liposomal Bupivacaine 13.3
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pacira Pharmaceuticals, Inc
Lead Sponsor
Dr. Jonathan Slonin
Pacira Pharmaceuticals, Inc
Chief Medical Officer since 2020
BSc in Biomedical Engineering and MD from University of Miami, MBA from George Washington University
Frank D. Lee
Pacira Pharmaceuticals, Inc
Chief Executive Officer since 2024
BSc in Chemical Engineering from Vanderbilt University, MBA from Wharton Graduate School of Business